Reproductive endocrinology: Metformin or thiazolidinedione therapy in PCOS?

  title={Reproductive endocrinology: Metformin or thiazolidinedione therapy in PCOS?},
  author={A. Grover and M. Yialamas},
  journal={Nature Reviews Endocrinology},
Insulin resistance has a key role in the pathogenesis of polycystic ovary syndrome, a common endocrinopathy that affects young women. Therefore, the use of insulin-sensitizing agents has been studied extensively in this patient population. Given the effectiveness of metformin and thiazolidinediones in previous studies, the question arises: is one class better than the other? 
Android Subcutaneous Adipose Tissue Topography in Females with Polycystic Ovary Syndrome: A Visible Phenotype Even in Juveniles
It is evident, that females with PCos, especially the overweight ones, have a higher risk for developing type 2 diabetes and it is suggested, that insulin resistance is even more common in overweight patients with PCOS that in lean females. Expand
Metformin associated lactic acidosis in Auckland City Hospital 2005 to 2009.
Lactic acidosis is an uncommon but significant complication of use of metformin which carries a high risk of morbidity and should be treated with caution. Expand
TLRs, macrophages, and NK cells: our understandings of their functions in uterus and ovary.
This review will briefly summarize the understanding of the functions of TLRs, macrophages and NK cells in uterus and ovary. Expand


Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta‐analysis
It is important to compare the efficacy and safety of ISDs such as metformin and thiazolidinediones for the treatment of polycystic ovary syndrome. Expand
Metformin in polycystic ovary syndrome
Overall, available data supports the therapeutic usefulness of metformin on cardiometabolic risk and reproduction assistance in PCOS women. Expand
Polycystic ovary syndrome.
This review addresses current concepts regarding the diagnosis, cause, and treatment of the polycystic ovary syndrome. Expand
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome
Findings fail to support the view that extended-release metformin, alone or combined with clomiphene citrate, improves live birth rates in previously infertile women with PCOS, and clomine alone seems preferable as first-line treatment for these patients despite a risk of multiple births. Expand
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
It is suggested that piog litazone is as effective as metformin in improving insulin sensitivity and hyperandrogenism, despite an increase in body weight, body mass index, and the waist to hip ratio associated with pioglitazone. Expand
Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.
Troglitazone improves the ovulatory dysfunction, hirsutism, hyperandrogenemia, and insulin resistance of PCOS in a dose-related fashion, with a minimum of adverse effects. Expand
Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome.
It is concluded that the MBS and its components are common in women with PCOS, placing them at increased risk for cardiovascular disease and different features that may reflect more severe insulin resistance. Expand
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
The ovulatory response to clomiphene can be increased in obese women with the polycystic ovary syndrome by decreasing insulin secretion with metformin. Expand
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
It is concluded that women with PCOS should periodically have an OGTT and must be closely monitored for deterioration in glucose tolerance, particularly among those with IGT, the subgroup at highest risk for subsequent development of NIDDM. Expand
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
Metformin is an effective treatment for anovulation in women with polycystic ovary syndrome and its choice as a first line agent seems justified, and there is some evidence of benefit on variables of the metabolic syndrome. Expand